Payment overview · 2025
General Payments
$479.10
14 reported records · 6 companies
Healthcare provider profile · identity verified
James H. Thomas, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SAVANNAH, TN · NPI 1457388985
Verified facts
What the public records show
CMS Open Payments records show James H. Thomas, M.D. received $479.10 in general payments during 2025 across 14 reported records.
Amgen Inc. accounted for 44.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $210.95 | 44.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $158.09 | 33.0% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.00 | 9.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.98 | 5.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.73 | 4.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.35 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $259.10 | 12 |
| Consulting Fee | $175.00 | 1 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $175.00 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $91.96 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $66.13 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $27.98 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.73 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.73 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
86 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
94 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
82 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
179 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1159 | 157 |
| Gabapentin | Gabapentin | 1014 | 140 |
| Metoprolol Tartrate | Metoprolol Tartrate | 827 | 131 |
| Pantoprazole Sodium | Pantoprazole Sodium | 813 | 206 |
| Furosemide | Furosemide | 698 | 122 |
| Atorvastatin Calcium | Atorvastatin Calcium | 695 | 166 |
| Potassium Chloride | Potassium Chloride | 551 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 520 | 134 |
| Lisinopril | Lisinopril | 498 | 131 |
| Famotidine | Famotidine | 442 | 125 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 430 | 115 |
| Lorazepam | Lorazepam | 429 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 392 | 82 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 387 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 381 | 100 |
| Alprazolam | Alprazolam | 377 | 43 |
| Tramadol Hcl | Tramadol Hcl | 350 | 62 |
| Losartan Potassium | Losartan Potassium | 338 | 82 |
| Metformin Hcl | Metformin Hcl | 317 | 80 |
| Clopidogrel | Clopidogrel Bisulfate | 315 | 76 |
| Azithromycin | Azithromycin | 290 | 184 |
| Omeprazole | Omeprazole | 287 | 73 |
| Simvastatin | Simvastatin | 264 | 56 |
| Prednisone | Prednisone | 257 | 120 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 230 | 33 |
| Buspirone Hcl | Buspirone Hcl | 222 | 43 |
| Allopurinol | Allopurinol | 218 | 56 |
| Sertraline Hcl | Sertraline Hcl | 214 | 48 |
| Trazodone Hcl | Trazodone Hcl | 205 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 199 | 50 |
| Clonazepam | Clonazepam | 195 | 17 |
| Warfarin Sodium | Warfarin Sodium | 181 | 25 |
| Eliquis | Apixaban | 179 | 25 |
| Baclofen | Baclofen | 170 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 168 | 50 |
| Mirtazapine | Mirtazapine | 163 | 40 |
| Glipizide | Glipizide | 162 | 38 |
| Spironolactone | Spironolactone | 159 | 48 |
| Ozempic | Semaglutide | 157 | 26 |
| Meloxicam | Meloxicam | 149 | 42 |
| Clonidine Hcl | Clonidine Hcl | 147 | 28 |
| Sucralfate | Sucralfate | 142 | 23 |
| Temazepam | Temazepam | 139 | 23 |
| Carvedilol | Carvedilol | 136 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 36 |
| Xarelto | Rivaroxaban | 128 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 127 | 27 |
| Ondansetron Odt | Ondansetron | 124 | 62 |
| Pioglitazone Hcl | Pioglitazone Hcl | 121 | 31 |
| Torsemide | Torsemide | 121 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 118 | 36 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 116 | 88 |
| Diclofenac Sodium | Diclofenac Sodium | 109 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 106 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 104 | 74 |
| Donepezil Hcl | Donepezil Hcl | 102 | 17 |
| Montelukast Sodium | Montelukast Sodium | 102 | 29 |
| Memantine Hcl | Memantine Hcl | 101 | 12 |
| Ibuprofen | Ibuprofen | 99 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 97 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 97 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 97 | 28 |
| Jardiance | Empagliflozin | 94 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 93 | 25 |
| Celecoxib | Celecoxib | 92 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 92 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 91 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 88 | 17 |
| Pentoxifylline | Pentoxifylline | 87 | 24 |
| Farxiga | Dapagliflozin Propanediol | 86 | suppressed |
| Pregabalin | Pregabalin | 84 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 17 |
| Trulicity | Dulaglutide | 82 | 15 |
| Methylprednisolone | Methylprednisolone | 81 | 70 |
| Atenolol | Atenolol | 78 | 18 |
| Glimepiride | Glimepiride | 77 | 18 |
| Gentamicin Sulfate | Gentamicin Sulfate | 76 | 39 |
| Risperidone | Risperidone | 75 | suppressed |
| Mupirocin | Mupirocin | 73 | 51 |
| Paroxetine Hcl | Paroxetine Hcl | 73 | 18 |
| Gemfibrozil | Gemfibrozil | 71 | 23 |
| Fluconazole | Fluconazole | 70 | 51 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 70 | 37 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 69 | 55 |
| Doxazosin Mesylate | Doxazosin Mesylate | 69 | 13 |
| Ezetimibe | Ezetimibe | 68 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 67 | 13 |
| Levofloxacin | Levofloxacin | 66 | 50 |
| Naproxen | Naproxen | 66 | 17 |
| Cefdinir | Cefdinir | 65 | 55 |
| Estradiol | Estradiol | 65 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 64 | 20 |
| Divalproex Sodium | Divalproex Sodium | 63 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 62 | 16 |
| Finasteride | Finasteride | 61 | 18 |
| Mounjaro | Tirzepatide | 60 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 58 | 21 |
| Januvia | Sitagliptin Phosphate | 57 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 15 |
| Fenofibrate | Fenofibrate | 55 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 53 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 11 |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 51 | 12 |
| Benazepril Hcl | Benazepril Hcl | 47 | 12 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 45 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 45 | 16 |
| Dexlansoprazole Dr | Dexlansoprazole | 44 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Diazepam | Diazepam | 43 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 32 |
| Alendronate Sodium | Alendronate Sodium | 42 | suppressed |
| Synthroid | Levothyroxine Sodium | 42 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 40 | 19 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 39 | 22 |
| Methocarbamol | Methocarbamol | 39 | suppressed |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Nitroglycerin | Nitroglycerin | 38 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | 14 |
| Minocycline Hcl | Minocycline Hcl | 37 | 30 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 13 |
| Megestrol Acetate | Megestrol Acetate | 36 | suppressed |
| Linzess | Linaclotide | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Methotrexate | Methotrexate Sodium | 34 | suppressed |
| Cephalexin | Cephalexin | 33 | 20 |
| Digoxin | Digoxin | 33 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 32 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 30 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Clotrimazole | Clotrimazole | 29 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Haloperidol | Haloperidol | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 24 | suppressed |
| Clonidine | Clonidine | 23 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 20 |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Phenobarbital | Phenobarbital | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Oxazepam | Oxazepam | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Glyburide | Glyburide | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | suppressed |
| Kelnor 1-35 | Ethynodiol D-Ethinyl Estradiol | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Nateglinide | Nateglinide | 14 | suppressed |
| Cimetidine | Cimetidine | 13 | suppressed |
| Dexilant | Dexlansoprazole | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Misoprostol | Misoprostol | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Captopril | Captopril | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $479.10 · 14 records | Amgen Inc. | AIRSUPRA, BREZTRI, Cologuard Collection Kit, NURTEC ODT, OTEZLA, PROLIA, REPATHA, TAVNEOS, VOQUEZNA, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error